SCHEMBL3940110

SCHEMBL3940110

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN(C)C)cc1)c1ccc2scnc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 3/20 0.34
NTRK1 P04629 4/20 0.34
NTRK2 Q16620 4/20 0.34
AAK1 Q2M2I8 1/20 0.33
PDE10A Q9Y233 2/20 0.33
CASP1 P29466 1/20 0.33
NAMPT P43490 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
RPS6KA2 Q15349 1/20 0.32
HSD11B1 P28845 1/20 0.32
SENP1 Q9P0U3 1/20 0.32
CRBN Q96SW2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3940114 1.00 KMT2A (0.36) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3935236 0.94 NPC1 (0.43) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3935232 0.94 NPC1 (0.43) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3934649 0.93 KMT2A (0.35) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3934638 0.93 KMT2A (0.35) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3944136 0.88 KMT2A (0.40) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3944130 0.88 KMT2A (0.40) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3940108 0.88 NOTUM (0.37) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL5858317 0.88 MAPT (0.39) KMT2ANPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL3934473 0.88 MAPT (0.39) KMT2ANPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 KMT2A 1839/4885NPC1 4723/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.